A Randomized, <scp>Placebo‐Controlled</scp> Phase <scp>III</scp> Extension Trial of the <scp>Long‐Term</scp> Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Abstract

This LTE study represents the longest placebo-controlled clinical trial performed in SLE to date. No new safety findings were identified in the LTE study, supporting the favorable benefit-risk profile of anifrolumab for patients with moderate-to-severe SLE receiving standard therapy.